Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Allergan, Inc.    AGN   US0184901025


Delayed Quote. Delayed Nyse - 10/24 04:00:32 pm
184.21 USD   +0.46%
1d ago ALLERGAN : Announces Quarterly Conference Call
4d ago Stronger oil stocks and surge in Shire lift FTSE
4d ago ALLERGAN : Valeant may up Allergan offer
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Allergan, Inc. : Reports on Allergan’s Continued Work on Hair Loss Product Despite Delays

03/07/2014 | 04:11am US/Eastern

(PRWEB) March 07, 2014

Allergan’s move to take part in the massive hair loss market is the subject of the latest report. The current lineup of Allergan products include JUVÉDERM®, BOTOX®, VIVITE®, SkinMedica®, NATRELLE® breast implants and LATISSE®. It is this last product that was the launching point for Allergan’s attempt to enter the hair loss market reports The active ingredient, bimatoprost was found to improve eyelash growth, and Allergan researchers are hoping it can do the same for hair.

The report also discusses the size of market itself and the opportunity that it poses for Allergan to increase its revenue by hundreds of millions of dollars. A hair loss product would open up an entirely new demographic for Allergan that includes millions of men in the U.S. alone. reports that early estimates suggest Allergan could generate upwards of $500 million a year by 2020 if they were able to get a hair loss product approved by the FDA.

Allergan started the FDA approval process with a first phase trial study in 2010. Despite not having FDA approval yet, reports that some doctors have already been using LATISSE off-label to treat male pattern baldness in patients that have allergic reactions to minoxidil-based products. Though Allergan’s bimatoprost hair loss product has shown promise, Allergan made the decision last year to put the third and final FDA trial phase on hold.

Given the disappointment with Allergan’s decision to put the bimatoprost hair loss product on hold it’s no surprise that the company still plans to move forward with research. David Pyott, Allergan’s Chief Executive, assured investors that the company would do more studies on the hair loss product before conducting late-stage FDA trials. Earlier this year Allergan announced they would be boosting research spending to $1 billion, which is an indicator that the company is still invested in creating a new hair loss product even though FDA trials have stalled.

To learn more about LATISSE products or to see the full report on Allergan’s move into the hair loss market, please visit:

About was created to provide a faster, less expensive and more convenient way to purchase authentic LATISSE® products. is able to accomplish this by having patients fill in a medical history form which a registered physician will review. This allows customers to purchase LATISSE® online without visiting a physician, saving customers time and money. is a subsidiary of Allied Medical & Diagnostic Services, LLC.

Read the full story at

(c) 2014 PRWEB.COM Newswire

Latest news on ALLERGAN, INC.
1d ago ALLERGAN : Announces Quarterly Conference Call
3d ago ALLERGAN : Patent Issued for Variable Cohesive Gel Form-Stable Breast Implant
3d ago ALLERGAN : Patent Issued for Interior Needle Stick Guard Stems for Tubes
3d ago ALLERGAN : Patent Issued for Compositions Containing Alpha-2-Adrenergic Agonist ..
3d ago ALLERGAN : Patent Issued for Biological Tissue Growth through Induced Tensile St..
3d ago ALLERGAN : Harvard Business Review Ranks David Pyott One of the Top 5 CEOs in th..
4d ago JOHN PAULSON : John Paulson's Solution To Shire Problem Probably Not Sitting Wel..
4d ago Stronger oil stocks and surge in Shire lift FTSE
4d ago ALLERGAN : Ackman, Valeant lawyers say Allergan CEO oversaw campaign to discredi..
4d ago ALLERGAN : Valeant may up Allergan offer
Duration : Period :
Allergan, Inc. Technical Analysis Chart | AGN | US0184901025 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes